Bottom line
CURE vs LABU: the short answer
CURE (Direxion Daily Healthcare Bull 3X ETF) and LABU (Direxion Daily S&P Biotech Bull 3X ETF) are both etfs.
But LABU is far broader, holding 163 positions to 67 for CURE, so beyond the top names it adds exposure CURE doesn't have.
CURE is cheaper at 0.94% vs 0.96% — a difference of $2.00 a year per $10,000 invested.
Over five years, CURE returned +8.6% a year vs −39.6% for LABU.
Updated Nov 19, 2026
CURE vs LABU side by side
| CURE | LABU | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.94% | 0.96% |
| Annual cost per $10k | $94 | $96 |
| 10-yr cost on $10k (prospectus) | $1,155 | $1,178 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +22.9% | +78.7% |
| 5-yr return (annualized) | +8.6% | −39.6% |
| 10-yr return (annualized) | +13.6% | −20.8% |
| Best quarter | +46.9% | +161.5% |
| Worst quarter | −45.8% | −67.4% |
| Net assets (fund) | $171.7M | $494.4M |
| Number of holdings | 67 | 163 |
| Portfolio turnover | 1% | 107% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | CURE | LABU | Difference |
|---|---|---|---|
| 2025 | +22.9% | +78.7% | −55.9% |
| 2024 | −8.5% | −25.9% | +17.4% |
| 2023 | −9.8% | −13.4% | +3.7% |
| 2022 | −20.4% | −80.3% | +59.9% |
| 2021 | +87.4% | −64.3% | +151.7% |
| 2020 | +5.1% | +74.7% | −69.6% |
| 2019 | +55.9% | +74.6% | −18.8% |
| 2018 | +2.9% | −57.3% | +60.2% |
| 2017 | +69.3% | +148.7% | −79.4% |
| 2016 | −17.4% | −63.0% | +45.6% |
Source: Fund prospectus bar charts
Holdings overlap
6 of CURE's top 25 holdings also appear in LABU's top 25.
| Holding | CURE | LABU |
|---|---|---|
| Dreyfus | 18.79% | 15.86% |
| N/a | 8.28% | 3.87% |
| Goldman Sachs Liq Es Fd A | 8.19% | 5.35% |
| Goldman Financial | 7.51% | 14.83% |
| N/a | 3.34% | 3.87% |
| N/a | 1.12% | 3.87% |
Source: SEC Form N-PORT
CURE top 10
- Dreyfus — 18.79%
- Eli Lilly & Company — 10.41%
- N/a — 8.28%
- Goldman Sachs Liq Es Fd A — 8.19%
- Goldman Financial — 7.51%
- Johnson & Johnson — 7.07%
- Abbvie Inc — 5.08%
- Unitedhealth Group Inc — 4.31%
- Merck & Company Inc — 3.68%
- N/a — 3.34%
LABU top 10
- Dreyfus — 15.86%
- Goldman Financial — 14.83%
- N/a — 9.63%
- N/a — 7.30%
- Goldman Sachs Liq Es Fd A — 5.35%
- N/a — 4.85%
- N/a — 3.87%
- Apogee Therapeutics Inc — 1.11%
- Oruka Therapeutics Inc — 1.03%
- Dianthus Therapeutics Inc — 0.96%
FAQ
What is the difference between CURE and LABU?
Which is cheaper, CURE or LABU?
Should I own both CURE and LABU?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.